» Articles » PMID: 19034577

Analysis of Differential BRAF(V600E) Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2008 Nov 27
PMID 19034577
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Papillary thyroid cancers often occur as microcarcinoma. Some papillary thyroid microcarcinoma (PTMC) have been considered to be high aggressive according to advanced disease stages, extrathyroidal extension, and severe cervical lymph node metastasis. Although several factors are thought to predict the occurrence of aggressiveness from PTMCs, the origin of aggressiveness has been rarely studied. To answer this question, the correlation between BRAF(V600E) mutation and high aggressive PTMCs was investigated. The clinicopathological characteristic of totally 64 cases of PTMCs was investigated and the BRAF(V600E) mutational status of them was identified. BRAF(V600E) mutation was exclusively detected in PTMCs (37.5%). The data provided no correlation between the occurrence of BRAF(V600E) mutations and clinicopathological parameters, such as sex, age, and tumor-like lesions combination. The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior. The BRAF(V600E) mutated PTMCs exhibited signs of higher aggressiveness than PTMCs without the mutation. BRAF(V600E) mutation may be a marker of high aggressiveness in PTMCs.

Citing Articles

Association of V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer.

Blazekovic I, Samija I, Perisa J, Gall Troselj K, Regovic Dzombeta T, Radulovic P Biomedicines. 2024; 12(3).

PMID: 38540091 PMC: 10968519. DOI: 10.3390/biomedicines12030477.


Nomogram prediction for cervical lymph node metastasis in multifocal papillary thyroid microcarcinoma.

Li W, Yu W, Du J, Teng D, Lin Y, Sui G Front Endocrinol (Lausanne). 2023; 14:1140360.

PMID: 37305060 PMC: 10254395. DOI: 10.3389/fendo.2023.1140360.


Association of BRAF Mutation with the Aggressive Behavior of Papillary Thyroid Microcarcinoma: A Meta-Analysis of 33 Studies.

Attia A, Hussein M, Issa P, Elnahla A, Farhoud A, Magazine B Int J Mol Sci. 2022; 23(24).

PMID: 36555268 PMC: 9779545. DOI: 10.3390/ijms232415626.


Risk and Prognostic Factors for BRAF Mutations in Papillary Thyroid Carcinoma.

Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y Biomed Res Int. 2022; 2022:9959649.

PMID: 35647194 PMC: 9132653. DOI: 10.1155/2022/9959649.


Tall Cell Variant versus Conventional Papillary Thyroid Carcinoma: A Retrospective Analysis in 351 Consecutive Patients.

Longheu A, Canu G, Cappellacci F, Erdas E, Medas F, Calo P J Clin Med. 2020; 10(1).

PMID: 33379135 PMC: 7794904. DOI: 10.3390/jcm10010070.